Science & Research
UC Davis Study Uncovers Genetic Mutation Affecting Immunotherapy Response in Solid Tumors
A study by UC Davis scientists reveals a genetic mutation that may explain why solid tumors are unresponsive to immunotherapy, potentially leading to more effective cancer treatments.
Oragenics Inc. Raises $16.5 Million to Advance Intranasal Concussion Therapy
Oragenics Inc. has successfully closed a $16.5 million public offering to fund the development of its intranasal therapy for concussions, marking a significant step forward in neurological disorder treatments.
Tonix Pharmaceuticals' TNX-1700 Shows Promise in Enhancing Immunotherapy for Gastric Cancer
Tonix Pharmaceuticals' preclinical data reveals TNX-1700's potential to improve immunotherapy outcomes in gastric cancer by targeting immunosuppressive neutrophils.
Soligenix Inc. Reports Promising Phase 3 Progress for HyBryte(TM) in CTCL Treatment
Soligenix Inc. shares encouraging interim results from its phase 3 trial of HyBryte(TM) for cutaneous T-cell lymphoma, highlighting potential advancements in treatment options for this rare disease.
GeoVax Advances Mpox Vaccine Development Amid Rising Global Cases
GeoVax Labs accelerates its GEO-MVA vaccine development for Mpox and smallpox, responding to global health threats and regulatory advancements.
Nutriband Inc. Advances in Opioid Safety with AVERSA(TM) Fentanyl Milestone
Nutriband Inc. achieves a significant milestone in the development of AVERSA(TM) Fentanyl, an abuse-deterrent opioid, marking progress in addressing the global opioid crisis.
InFlectis BioScience's IFB-088 Shows Promise in ALS Treatment Through Groundbreaking Study
InFlectis BioScience's study on IFB-088 demonstrates potential in addressing TDP-43 proteinopathy, offering hope for ALS patients by improving motor neuron survival and function.
Goliath Resources Reports Visible Gold at Golddigger Property, Expands 2025 Drill Program
Goliath Resources Limited, backed by McEwen Mining Inc., has discovered six new visible gold occurrences at its Golddigger Property in British Columbia, prompting an expansion of its 2025 drill program to explore the full potential of the Surebet system.
Steel Solutions: The Backbone of Modern Civil Engineering Projects
Steel's unparalleled strength, durability, and versatility make it a cornerstone material in civil engineering, offering sustainability, cost efficiency, and safety benefits.
Equine Therapy Explored in New Memoir Highlights Healing Power of Horses
Anna's memoir delves into the transformative power of equine therapy, offering insights into emotional and spiritual healing through the bond between humans and horses.
6th Clinical Trial Agreements Summit to Address Key Industry Challenges
The upcoming 6th Clinical Trial Agreements Summit in Philadelphia will tackle critical issues like budgetary negotiations, intellectual property protection, and risk reduction in clinical trials, featuring insights from over 30 industry experts.
New Study Reveals Pesticides' Impact on Gut Microbes and Inflammation
A preclinical study highlights how pesticide compounds disrupt gut bacteria linked to inflammation, offering potential insights for biotech R&D.
Oragenics Inc. Announces $20 Million Preferred Stock and Warrant Offering to Fund Concussion Trials and R&D
Oragenics Inc. secures up to $20 million through a preferred stock and warrant offering to advance its ONP-2 concussion trials and support R&D efforts.
Aurania Resources Identifies Promising Copper Anomalies in Ecuador
Aurania Resources' use of advanced 2D inversion technology at its Awacha site in Ecuador reveals six conductive anomalies, signaling potential for significant porphyry copper discoveries.
GeoVax Announces $6 Million Public Offering to Advance Immunotherapies and Vaccines
GeoVax Labs, Inc. secures approximately $6 million in a public offering to fund the development of its immunotherapies and vaccines against cancer and infectious diseases.
Soligenix Inc. Advances Novel Immunotherapy to Combat Antibiotic Resistance
Soligenix Inc. is developing SGX943, a novel immunotherapy that enhances the body's immune response to combat bacterial infections, addressing the critical challenge of antibiotic resistance.
Cardiovascular Disease Risk Factors on the Rise Despite Medical Advances
The American Heart Association's 2025 report highlights increasing risk factors for cardiovascular diseases, signaling a pressing public health challenge.
Clene Inc. Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs
Clene Inc. progresses in its regulatory strategy for CNM-Au8, with FDA meetings set to discuss ALS and MS treatments, marking a significant step towards potential accelerated approval.
James Ernest Brown's Pyramid Film 'Fire in Middle' Wins Bronze Telly Award
James Ernest Brown's short film 'Fire in Middle,' challenging traditional views on the purpose of Egypt's pyramids, wins a Bronze Telly Award, offering a new perspective on ancient architectural marvels.
University of Plymouth Researchers Identify Proteins Linked to Brain Tumor Growth
Researchers at the University of Plymouth have discovered proteins crucial for the growth of common brain tumors, paving the way for less invasive treatments.
Calidi Biotherapeutics Inc. Advances Oncology Pipeline and Strategic Goals in 2025
Calidi Biotherapeutics Inc. outlines significant progress in its oncology immunotherapy pipeline and strategic initiatives aimed at enhancing shareholder value and advancing cancer treatment options.
SeaStar Medical's QUELIMMUNE Shows Promise in Treating Pediatric AKI
SeaStar Medical's QUELIMMUNE device, approved by the FDA, significantly reduces mortality rates in pediatric patients with acute kidney injury (AKI) by targeting the cytokine storm at its source.
SeaStar's QUELIMMUNE Shows Promise in Halving Pediatric Sepsis Mortality Rates
SeaStar Medical's QUELIMMUNE therapy, approved by the FDA in 2024, has demonstrated the potential to reduce pediatric sepsis mortality rates by half, offering hope for critically ill children with acute kidney injury.
Scinai Immunotherapeutics Ltd. Highlights PC111 Breakthrough Following Top Italian Dermatology Award
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) celebrates Dr. Roberta Lotti's award-winning research on PC111, a promising treatment for pemphigus vulgaris, underscoring its potential as a non-immunosuppressive therapy for autoimmune skin conditions.
Annovis Bio Inc. to Showcase Alzheimer’s Research at AAIC 2025
Annovis Bio Inc. will present significant advancements in Alzheimer’s treatment at the Alzheimer’s Association International Conference 2025, highlighting the potential of its lead candidate, buntanetap.
Emperor Metals Inc. Identifies Dual Gold Trends at Duquesne West Property
Emperor Metals Inc. and Globex Mining Enterprises Inc. have identified two high-grade gold mineralization trends at the Duquesne West Property in Quebec, signaling potential for a new resource calculation.
Growing Public Interest in Mitochondrial Function Testing Highlights Advances in Health and Longevity
The increasing public interest in mitochondrial health testing underscores significant advancements in addressing mitochondrial dysfunction and its implications for overall wellness and longevity.
NeuroSense Therapeutics Advances Toward Canadian Fast-Track Approval for ALS Drug PrimeC
NeuroSense Therapeutics' progress with Health Canada for its ALS drug PrimeC could accelerate approval and bolster a significant pharmaceutical partnership, highlighting a pivotal moment for ALS treatment and the biotech sector.
BiomX Inc.: A Biotech Pioneer with Pentagon Backing and Promising Phage Therapy
BiomX Inc. (NYSE: PHGE), a biotech company with a market cap of $13 million, has secured $40 million in non-dilutive funding from the U.S. Defense Health Agency, highlighting its potential in addressing antibiotic-resistant infections with phage therapy.
ABVC BioPharma CEO Recognized Among Influential Indian-Origin CEOs in Global Biotech
Dr. Uttam Patil, CEO of ABVC BioPharma, is highlighted for his leadership in advancing a novel botanical antidepressant, ABV-1504, which could revolutionize treatment for Major Depressive Disorder by eliminating suicidal ideation side effects.